Fig. 3: PK and PD profile of EMB-02. | British Journal of Cancer

Fig. 3: PK and PD profile of EMB-02.

From: First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors

Fig. 3

a The mean serum EMB-02 concentration following a single intravenous infusion at the tested dose levels (Semilogarithmic scale). b PD-1 receptor occupancy by EMB-02 on CD3 + T cells among patients treated at various doses. Data represent the mean + SD for each cohort. Notes: thirteen patients who had anti-PD-(L)1 treatment within four months of starting the study treatment and had higher pre-dose concentration were excluded from the PK concentration summary. Additionally, the PD-1 receptor occupancy data for seventeen patients were excluded from the analysis due to various reasons, including missing samples, extremely low levels of PD-1 expression, and prior treatment with other anti-PD-1 drugs within approximately three months before the first administration of EMB-02.

Back to article page